Silibinin Radiosensitizes EGF Receptor-knockdown Prostate Cancer Cells by Attenuating DNA Repair Pathways

Mohit Rajput1, Deepali Mishra1, Kunal Kumar1

  • 1Cancer Biology Laboratory, School of Life Sciences, New Delhi, India.

Insights

Silibinin enhances prostate cancer cell radiosensitivity by targeting DNA repair and survival pathways in EGFR-knockdown cells. This study reveals a novel mechanism for silibinin in overcoming radioresistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Prostate cancer (PCa) radioresistance is a significant clinical challenge.
  • Epidermal Growth Factor Receptor (EGFR) signaling contributes to radioresistance in PCa.
  • Targeting DNA repair and survival pathways is crucial for overcoming radioresistance.

Purpose of the Study:

  • To investigate the radiosensitizing effects of silibinin in EGFR-knockdown prostate cancer cells.
  • To elucidate the mechanisms by which silibinin overcomes radiation-induced resistance.
  • To assess silibinin's impact on DNA repair pathways (HR and NHEJ) and pro-survival signaling.

Main Methods:

  • EGFR knockdown in radioresistant PCa DU145 cells using shRNA.
  • Assessment of ionizing radiation (IR) and silibinin effects using clonogenic and trypan blue assays.
  • Analysis of DNA repair, cell cycle, and protein expression via flow cytometry, comet assay, and immunoblotting.

Main Results:

  • Silibinin decreased colony formation and increased cell death in IR-exposed, EGFR-knockdown PCa cells.
  • Silibinin induced G2/M phase cell cycle arrest and downregulated Rad51 and DNA-PK protein expression.
  • Silibinin suppressed pro-survival signaling pathways, including ERK1/2, Akt, and STAT3.

Conclusions:

  • Silibinin acts as a radiosensitizer in EGFR-knockdown PCa cells.
  • Silibinin targets both homologous recombination and non-homologous end joining DNA repair pathways.
  • Silibinin effectively suppresses key pro-survival signaling pathways, offering a novel therapeutic strategy for overcoming PCa radioresistance.